UCB.BR
UCB S.A.
Brussels
71.000.25 (0.35%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close70.75
Open68.74
Bid64.00 x 203800
Ask66.00 x 10000
52wk Range61.60 - 86.05
Day's Range68.74 - 71.25
Volume164,646
Avg Vol (3m)307,136
As of 11:35 AM EDT. Market closed.
  • Reuters2 months ago

    UCB faces U.S. patent challenge for epilepsy drug

    The U.S. Patent and Trademark Office (PTO) is to review UCB's patent for its epilepsy drug Vimpat, the latest round in a legal battle between the Belgian pharmaceutical company and generic rivals. U.S. pharmaceuticals group Argentum Pharmaceuticals, which challenged UCB's patent, said in a statement late on Monday that the PTO had granted approval for a review of the sole remaining U.S. patent of UCB's Vimpat drug, due to expire in March 2022.

  • The Wall Street Journal3 months ago

    [$$] Clinical Development News, May 2-6

    The following is a list of clinical development news from private and public companies during the week of May 2-6.